Marsh & McLennan stock faces margin pressure and cyclical insurance headwinds, underperforming the broader S&P 500 index despite maintaining a Moderate Buy consensus from analysts.
Despite a 6.3% rise over the past three months, Marsh & McLennan has declined 5.9% YTD and 11.6% over 52 weeks, underperforming the S&P 500 amid margin and leverage concerns.
Aon's stock has decreased 17.3% over the past 52 weeks and 16.1% YTD, lagging behind Marsh & McLennan's performance.
The S&P 500 has risen 11.6% YTD and 15.7% over the past 52 weeks, serving as the benchmark against which Marsh & McLennan's underperformance is measured.
Marsh & McLennan shares have struggled in 2024, posting a 5.9% year-to-date decline and trailing the S&P 500's 11.6% gain. Despite a recent 6.3% rally over the last three months, the insurance giant faces persistent headwinds from rising operational costs, talent retention expenses, and elevated leverage following recent acquisitions.
The company is facing margin compression due to higher talent retention costs, increased acquisition-related expenses, and cyclical weakness in property and casualty insurance pricing.
Marsh & McLennan has outperformed Aon, which has seen a steeper decline of 17.3% over the past 52 weeks compared to Marsh & McLennan's 11.6% drop.